SG11201607894RA - S1p modulator immediate release dosage regimen - Google Patents

S1p modulator immediate release dosage regimen

Info

Publication number
SG11201607894RA
SG11201607894RA SG11201607894RA SG11201607894RA SG11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA SG 11201607894R A SG11201607894R A SG 11201607894RA
Authority
SG
Singapore
Prior art keywords
modulator
immediate release
dosage regimen
release dosage
regimen
Prior art date
Application number
SG11201607894RA
Other languages
English (en)
Inventor
Eric Legangneux
Erik Wallstroem
Philippe Michael Rene Bouillot
Emeric Reynaud
Frank Dahlke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607894R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201607894RA publication Critical patent/SG11201607894RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201607894RA 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen SG11201607894RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
SG11201607894RA true SG11201607894RA (en) 2016-10-28

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607894RA SG11201607894RA (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Country Status (16)

Country Link
US (3) US20170027907A1 (ko)
EP (3) EP4074312A1 (ko)
JP (1) JP6674903B2 (ko)
KR (2) KR20160141841A (ko)
CN (2) CN116650467A (ko)
AU (2) AU2015246036A1 (ko)
CA (1) CA2943598C (ko)
CL (1) CL2016002562A1 (ko)
IL (2) IL305337A (ko)
MX (1) MX2016013245A (ko)
PH (1) PH12016501965A1 (ko)
RU (2) RU2020107732A (ko)
SG (1) SG11201607894RA (ko)
TW (1) TW201622721A (ko)
WO (1) WO2015155709A1 (ko)
ZA (1) ZA201606519B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170027907A1 (en) * 2014-04-10 2017-02-02 Eric Legangneux Sip modulator immediate release dosage regimen
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP2020535147A (ja) * 2017-09-29 2020-12-03 ノバルティス アーゲー シポニモドの投与レジメン
WO2019064217A1 (en) * 2017-09-29 2019-04-04 Novartis Ag DOSAGE DIAGRAM OF SIPONIMOD
US20210369732A1 (en) * 2018-03-01 2021-12-02 Astrazeneca Ab PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4-OXAZEPANE-2-CARBOXAMIDE
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53041B (en) * 2008-12-18 2014-04-30 Novartis Ag 1- [4- [1- (4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXYIMINO) -ETHYL] -2-ETHYL-BENZYL] -AZETIDINE-3-CARBOXYLIC ACID
PL3409274T3 (pl) * 2008-12-22 2020-06-01 Novartis Ag Schemat dawkowania dla agonisty receptora s1p
JO3044B1 (ar) * 2008-12-22 2016-09-05 Novartis Ag نظام تناول جرعة لمنبه مستقبل s1p
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
LT2661261T (lt) * 2011-01-07 2019-10-25 Novartis Ag Imunosupresantų kompozicijos
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
JP2014530835A (ja) * 2011-10-21 2014-11-20 ノバルティスアーゲー Ｓ１ｐ受容体モジュレーターまたはｓ１ｐ受容体アゴニストのための投薬量レジメン
US20170027907A1 (en) * 2014-04-10 2017-02-02 Eric Legangneux Sip modulator immediate release dosage regimen

Also Published As

Publication number Publication date
RU2020107732A (ru) 2020-03-30
JP6674903B2 (ja) 2020-04-01
RU2715734C2 (ru) 2020-03-03
IL247986A0 (en) 2016-11-30
JP2017510607A (ja) 2017-04-13
EP3831378A1 (en) 2021-06-09
CN116650467A (zh) 2023-08-29
EP4074312A1 (en) 2022-10-19
MX2016013245A (es) 2017-01-16
US20170027907A1 (en) 2017-02-02
KR20220156981A (ko) 2022-11-28
AU2015246036A1 (en) 2016-10-13
IL305337A (en) 2023-10-01
CA2943598A1 (en) 2015-10-15
RU2016143979A (ru) 2018-05-14
CN106456552A (zh) 2017-02-22
CA2943598C (en) 2023-03-07
ZA201606519B (en) 2017-11-29
AU2020203107B2 (en) 2021-10-21
US20220016076A1 (en) 2022-01-20
RU2016143979A3 (ko) 2018-11-12
KR20160141841A (ko) 2016-12-09
CL2016002562A1 (es) 2017-07-28
PH12016501965A1 (en) 2017-01-09
AU2020203107A1 (en) 2020-05-28
EP3129020A1 (en) 2017-02-15
US20190054065A1 (en) 2019-02-21
WO2015155709A1 (en) 2015-10-15
TW201622721A (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
IL247986A0 (en) A therapeutic regimen containing an immediate release dose of an s1p modulator
GB201404922D0 (en) Pharmaceutical compounds
SI3022458T1 (sl) Povezava zavornega diska in pesta
SI3145836T1 (sl) Dajalna kapsula
PL3363428T3 (pl) Perfuzyjna postać dawkowania
HK1215385A1 (zh) 改進釋放的被覆蓋的膠囊
GB201416513D0 (en) Pharmaceutical compounds
IL247084A0 (en) dose fgh–18
GB201412955D0 (en) Supramolecular capsules
SI3145499T1 (sl) Obložene kapsule s prirejenim sproščanjem
GB201417707D0 (en) Pharmaceutical compounds
GB201418710D0 (en) Dosage regimen
EP3011948A4 (en) DEVICE FOR DISPENSING RADIOPHARMACEUTICAL PRODUCTS
PL3215437T3 (pl) Urządzenie dozujące
GB2531773B (en) Medicine pack
GB201418708D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201508022D0 (en) Pharmaceutical compounds
AU362816S (en) Capsule
GB201416968D0 (en) Pharmaceutical compounds
GB201416969D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds